KDR-in-4 is primarily utilized in research settings as a selective inhibitor targeting kinase insert domain receptor (KDR), which is also known as vascular endothelial growth factor receptor 2 (VEGFR2). Its application is significant in studies focused on angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting VEGFR2, KDR-in-4 helps researchers understand the role of this receptor in various pathological conditions, including cancer, where angiogenesis is a critical factor in tumor growth and metastasis. Additionally, it is used in preclinical studies to evaluate potential therapeutic strategies for diseases characterized by abnormal blood vessel formation, such as diabetic retinopathy and age-related macular degeneration. The compound serves as a valuable tool in the development of anti-angiogenic drugs, providing insights into the mechanisms of VEGFR2 signaling and its inhibition.